TriLink BioTechnologies, a Maravai LifeSciences company and global provider of reagents and services to the life sciences, has partnered with Avantor a global leader in mission-critical products and services for life sciences and advanced technology customers, to expand the availability of its innovative nucleic acid products to customers in Europe, the Middle East and Africa (EMEA). This distribution partnership is designed to improve the ordering process and provide shorter delivery times for European customers, increasing access to TriLink’s novel nucleic acid technologies.
With over 25 years of experience in the development and manufacturing of nucleic acid products, TriLink is an established industry leader focused on advancing mRNA-based therapeutic innovations. Through the agreement, TriLink’s products will now be more widely available in the EMEA region, including its CleanCap analogues (co-transcriptional mRNA caps), catalog mRNAs, over 150 modified and unmodified nucleotides, and powerful IVT enzymes such as CleanScribe RNA polymerase – all of which can be customized for research use (RUO) or manufactured to GMP quality. In addition, TriLink products will be available through VWR’s MarketSource e-commerce platform in the coming months.
Also Read: Be Bio Closes $92M Series C, Transitions to Clinical Stage
“This partnership is an important step in expanding access to our cutting-edge nucleic acid technologies across Europe,” said Becky Buzzeo, Chief Commercial Officer at TriLink. “By working with a trusted partner like Avantor and leveraging its unmatched distribution network, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research.”
TriLink is committed to advancing nucleic acid therapeutics, vaccines and diagnostics by providing its customers with high-quality technology and chemistry, as well as contract development and manufacturing organization (CDMO) services. The growing portfolio of mRNA capping analogues includes the award-winning CleanCap M6 , mRNA raw materials (nucleotides and other IVT enzymes, including wild-type T7 RNA polymerase), advanced scale-up capabilities and unmatched expertise in mRNA, oligonucleotide and enzyme production.
SOURCE: Businesswire